Repligen Corporation (RGEN)
NASDAQ: RGEN · Real-Time Price · USD
140.81
+1.91 (1.38%)
Nov 21, 2024, 12:09 PM EST - Market open

Company Description

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally.

It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes.

It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths.

Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands.

The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations.

Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands.

The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Repligen Corporation
Repligen logo
Country United States
Founded 1981
Industry Medical Instruments & Supplies
Sector Healthcare
Employees 1,783
CEO Olivier Loeillot

Contact Details

Address:
Building 1, Suite 100
Waltham, Massachusetts 02453
United States
Phone 781 250 0111
Website repligen.com

Stock Details

Ticker Symbol RGEN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000730272
CUSIP Number 759916109
ISIN Number US7599161095
Employer ID 04-2729386
SIC Code 2836

Key Executives

Name Position
Olivier Loeillot President, Chief Executive Officer and Director
Anthony J. Hunt Executive Chair
Jason K. Garland Chief Financial Officer and Chief Compliance Officer
James R. Bylund Chief Operating Officer
Ralf Kuriyel Senior Vice President of Research and Development
Keith Lee Robinson Chief Information Officer
Sondra S. Newman Global Head of Investor Relations
Kimberly A. Cornwell Global Head of Legal
Neil Whitfield Vice President and Global Head of Sales
Leslie Galvin Vice President of Human Resources

Latest SEC Filings

Date Type Title
Nov 18, 2024 10-Q Quarterly Report
Nov 18, 2024 10-Q/A [Amend] Quarterly report
Nov 18, 2024 10-Q/A [Amend] Quarterly report
Nov 18, 2024 10-K/A [Amend] Annual report
Nov 18, 2024 10-Q/A [Amend] Quarterly report
Nov 18, 2024 10-Q/A [Amend] Quarterly report
Nov 18, 2024 10-Q/A [Amend] Quarterly report
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals